Hospital
Natchez Hospital Company LLC
Natchez Hospital Company LLC was paid $17.50M by Medicaid between Jan 2018 and Dec 2024, across 171 billing codes. Its largest line is 99283, emergency room visit (moderate) — 26% of everything it billed.
33Billing provider infoNATCHEZ HOSPITAL COMPANY LLC
NATCHEZ, MS 39120
NATCHEZ, MS 39120
33aNPI1164821559assigned 08/21/2014
33bProvider typeGeneral Acute Care Hospital
28Total paid$17.50M
24GClaims460,001
24DCodes billed171
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Mississippi
Rank by total paid#28 of 77
Median peer was paid$8.23M
This provider vs. median2.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LALOR, PAULA controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 80,427 | $3.18M | |
| 2019 | 75,281 | $3.18M | |
| 2020 | 58,572 | $2.19M | |
| 2021 | 57,096 | $2.22M | |
| 2022 | 72,235 | $2.42M | |
| 2023 | 67,808 | $2.51M | |
| 2024incomplete | 48,582 | $1.81M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 26% | 30,020 | 25,436 | $4.53M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 15% | 14,353 | 11,945 | $2.63M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.3% | 5,329 | 4,363 | $1.10M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 4.3% | 21,144 | 4,190 | $752K |
| G0378 | Hospital observation service, per hour | 3.6% | 1,571 | 1,207 | $629K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.5% | 7,521 | 6,429 | $617K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.0% | 6,832 | 5,601 | $522K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 2.4% | 8,036 | 1,693 | $428K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 2.2% | 4,362 | 2,887 | $393K |
| 71045 | Radiologic examination, chest; single view | 2.1% | 10,706 | 8,861 | $362K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2.1% | 9,791 | 7,841 | $360K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.9% | 4,517 | 3,468 | $337K |
159 more codes
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.6% | 6,287 | $289K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.5% | 2,797 | $259K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1.5% | 8,812 | $258K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.4% | 5,309 | $253K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.4% | 1,668 | $247K |
| 71046 | Radiologic examination, chest; 2 views | 1.3% | 5,648 | $228K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.3% | 12,135 | $226K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.2% | 4,706 | $216K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.1% | 790 | $201K |
| 80053 | Comprehensive metabolic panel | <1% | 21,894 | $166K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 30,166 | $158K |
| 86900 | <1% | 2,816 | $144K | |
| 87400 | <1% | 10,243 | $142K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 6,215 | $132K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,317 | $130K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,471 | $120K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 7,002 | $110K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 2,908 | $97K |
| 36415 | Collection of venous blood by venipuncture | <1% | 31,956 | $82K |
| 87430 | <1% | 5,629 | $74K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,681 | $65K |
| 72100 | <1% | 1,291 | $63K | |
| 74018 | <1% | 1,422 | $60K | |
| D2930 | Prefabricated stainless steel crown - primary tooth | <1% | 968 | $60K |
| 83880 | <1% | 2,420 | $53K | |
| 84484 | <1% | 6,638 | $49K | |
| 86850 | <1% | 2,054 | $48K | |
| 81001 | <1% | 19,121 | $44K | |
| 86901 | <1% | 2,698 | $43K | |
| 73030 | <1% | 1,118 | $41K | |
| 73630 | <1% | 900 | $37K | |
| 81025 | <1% | 5,183 | $32K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 5,809 | $31K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 617 | $30K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 753 | $28K |
| 87807 | <1% | 2,338 | $26K | |
| 97162 | <1% | 843 | $26K | |
| 87040 | <1% | 3,731 | $25K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,230 | $24K |
| 80305 | <1% | 2,966 | $24K | |
| 82553 | <1% | 2,565 | $21K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 629 | $21K |
| 73562 | <1% | 573 | $21K | |
| 97116 | <1% | 1,565 | $19K | |
| 85730 | <1% | 4,650 | $18K | |
| 82550 | <1% | 3,183 | $16K | |
| 83690 | <1% | 3,385 | $16K | |
| 73610 | <1% | 334 | $15K | |
| 36600 | <1% | 346 | $14K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,363 | $14K |
| 73560 | <1% | 413 | $14K | |
| 85610 | <1% | 5,301 | $13K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 157 | $13K |
| 82962 | <1% | 6,514 | $13K | |
| 87077 | <1% | 2,143 | $12K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 153 | $12K |
| 83605 | <1% | 1,862 | $11K | |
| 85379 | <1% | 1,815 | $11K | |
| 83735 | <1% | 3,393 | $10K | |
| 73130 | <1% | 242 | $10K | |
| 59025 | Fetal non-stress test | <1% | 80 | $10K |
| 71250 | <1% | 359 | $10K | |
| D3220 | Therapeutic pulpotomy (excluding final restoration) - removal of pulp coronal to the dentinocemental junction | <1% | 245 | $9K |
| 82150 | <1% | 2,199 | $9K | |
| 84702 | <1% | 821 | $9K | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 78 | $8K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 151 | $8K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 120 | $8K |
| 87186 | <1% | 908 | $7K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,204 | $7K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,088 | $7K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 14 | $7K |
| 80061 | Lipid panel | <1% | 594 | $6K |
| 93971 | <1% | 164 | $6K | |
| 82077 | <1% | 594 | $6K | |
| 73502 | <1% | 209 | $6K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 83 | $6K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 298 | $5K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 84 | $5K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 72 | $5K |
| 76642 | <1% | 116 | $5K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 201 | $4K |
| 82803 | <1% | 356 | $4K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 47 | $3K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 68 | $3K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 91 | $3K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 90 | $3K |
| 97161 | <1% | 55 | $3K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 746 | $3K |
| 36430 | <1% | 18 | $3K | |
| 76770 | <1% | 47 | $2K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 42 | $2K |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 20 | $2K |
| 73590 | <1% | 48 | $2K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 14 | $2K |
| 72040 | <1% | 45 | $2K | |
| 86920 | <1% | 16 | $2K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 33 | $1K |
| 76536 | <1% | 35 | $1K | |
| 72131 | <1% | 29 | $1K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 2,441 | $1K |
| 93925 | <1% | 13 | $1K | |
| 84703 | <1% | 165 | $912.54 | |
| 70486 | <1% | 18 | $864.67 | |
| 72070 | <1% | 12 | $856.80 | |
| 80143 | <1% | 55 | $663.17 | |
| 80179 | <1% | 55 | $646.39 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,137 | $596.58 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 4,182 | $538.61 |
| 87070 | <1% | 68 | $528.33 | |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 1,743 | $519.91 |
| D2391 | Resin-based composite - one surface, posterior, primary or permanent | <1% | 18 | $491.64 |
| 51702 | <1% | 30 | $473.87 | |
| 96376 | <1% | 2,265 | $455.83 | |
| 73110 | <1% | 17 | $390.03 | |
| 96367 | <1% | 13 | $353.89 | |
| 82607 | <1% | 27 | $293.81 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,753 | $225.75 |
| 86140 | <1% | 77 | $196.17 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 6,166 | $134.10 |
| 84550 | <1% | 38 | $130.67 | |
| 85651 | <1% | 41 | $123.54 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 14 | $99.23 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,115 | $77.23 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 369 | $63.56 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,427 | $52.95 |
| 81003 | <1% | 23 | $24.42 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 1,099 | $19.18 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,777 | $16.87 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,207 | $16.80 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 231 | $2.46 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,679 | $0.64 |
| J2704 | Injection, propofol, 10 mg | 0% | 2,826 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 1,114 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 1,268 | $0.00 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 110 | $0.00 |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | 0% | 188 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 95 | $0.00 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 462 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 91 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 54 | $0.00 |
| 96368 | 0% | 12 | $0.00 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 22 | $0.00 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 44 | $0.00 |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 93 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 24 | $0.00 |
| J0290 | Injection, ampicillin sodium, 500 mg | 0% | 536 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 52 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 29 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 39 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 505 | $0.00 |
| 90714 | 0% | 70 | $0.00 | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 14 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 163 | $0.00 |
| 99218 | 0% | 42 | $0.00 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 17 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 30 | $0.00 |
| 90715 | 0% | 12 | $0.00 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLALOR, PAULA (DIRECTOR/DELEGATED OFFICIAL)
| Provider | Location | Paid |
|---|---|---|
| Roswell Hospital Corporation | Roswell, NM | $41.27M |
| Wesley Health System LLC | Hattiesburg, MS | $37.82M |
| Metro Knoxville Hma LLC | Powell, TN | $28.70M |
| Bullhead City Hospital Corporation | Bullhead City, AZ | $28.54M |
| Iom Health System LP | Fort Wayne, IN | $27.50M |
| ST. Joseph Health System, LLC | Fort Wayne, IN | $25.43M |
| Laredo Texas Hospital Company LP | Laredo, TX | $19.46M |
| Oak Hill Hospital Corporation | Oak Hill, WV | $18.77M |
| Cocke County Hma, LLC | Newport, TN | $18.34M |
| Cleveland Tennessee Hospital Company LLC | Cleveland, TN | $16.31M |
| Jefferson County Hma LLC | Jefferson City, TN | $14.31M |
| Northwest Arkansas Hospitals, LLC | Springdale, AR | $11.46M |
| Petersburg Hospital Company LLC | Petersburg, VA | $11.20M |
| Campbell County Hma, LLC | Lafollette, TN | $10.07M |
| Warsaw Health System LLC | Warsaw, IN | $9.95M |
| Longview Medical Center LP | Longview, TX | $9.29M |
| Moberly Hospital Company LLC | Moberly, MO | $8.61M |
| Crestview Hospital Company, LLC | Crestview, FL | $8.15M |
| Kirksville Missouri Hospital Company, LLC | Kirksville, MO | $7.98M |
| Victoria of Texas LP | Victoria, TX | $7.74M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.